Research Analysts Offer Predictions for TSE:GUD Q4 Earnings

Knight Therapeutics Inc. (TSE:GUD) – Equities researchers at Raymond James issued their Q4 2024 earnings per share estimates for shares of Knight Therapeutics in a note issued to investors on Wednesday, November 13th. Raymond James analyst R. Sarugaser anticipates that the company will earn $0.01 per share for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Raymond James also issued estimates for Knight Therapeutics’ Q1 2025 earnings at $0.00 EPS and Q3 2025 earnings at $0.00 EPS.

Other equities analysts also recently issued reports about the company. Stifel Canada upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th. Stifel Nicolaus upgraded shares of Knight Therapeutics from a “hold” rating to a “buy” rating and increased their price objective for the stock from C$5.75 to C$6.75 in a report on Tuesday, August 13th.

Knight Therapeutics Stock Performance

Shares of TSE GUD opened at C$5.19 on Friday. The company has a 50-day simple moving average of C$5.71 and a 200-day simple moving average of C$5.73. The company has a debt-to-equity ratio of 7.62, a current ratio of 3.41 and a quick ratio of 1.79. The company has a market cap of C$525.28 million, a PE ratio of -25.95, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics has a 12 month low of C$5.07 and a 12 month high of C$6.23.

Insider Buying and Selling

In other news, Director Samira Sakhia acquired 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average cost of C$5.15 per share, for a total transaction of C$103,000.00. Also, insider Sime Armoyan bought 90,300 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was purchased at an average price of C$5.13 per share, with a total value of C$463,672.44. Corporate insiders own 45.62% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.